Navigation Links
Study Finds No Conclusive Benefit from Treating Kleptomania

A small clinical trial of a medication to treat kleptomania has failed to find any conclusive benefit for patients with the impulsive stealing disorder,// according to researchers at the Stanford University School of Medicine.

But the results leave open the possibility that some medications, including the one in the trial, may still be an effective treatment for certain patients.

More than 1.2 million people in the United States are thought to suffer from kleptomania, the guilt-ridden, impulsive stealing of inexpensive and unneeded items. The condition differs from shoplifting, in which the action is usually planned and motivated by need or monetary gain. People suffering from kleptomania often fail to seek treatment for fear of legal repercussions.

The medication in the trial was escitalopram, marketed as. The drug belongs to a class of antidepressants known as selective serotonin reuptake inhibitors, and earlier studies have suggested that SSRIs can be effective in treating some impulse control disorders, such as skin picking. In an earlier, non-blinded open-label phase of the kleptomania study, when trial participants were aware that they were taking escitalopram and not a placebo, 78 percent of the patients responded to the drug.

In the second phase of the study, conducted as a double-blind, placebo-controlled trial, the benefit was not seen.

"When we randomized people to drug vs. placebo, the same proportion of people relapsed on drug as relapsed on placebo, suggesting that it was really a placebo response in the initial phase of the study," said Lorrin Koran, MD, professor of psychiatry and behavioral sciences and first author of the study, which will be published in the March issue of the Journal of Clinical Psychiatry.

In the double-blind trial, 15 subjects were assigned to receive either a placebo or escitalopram. For both groups, the relapse rates were effectively the same, with three o f seven patients on the drug relapsing, compared with four of eight on the placebo.

Koran says that the small number of subjects in the study makes it impossible to know with certainty whether the results of the trial are really indicative of the effectiveness of escitalopram.

"For some people, I think these drugs really do work. And for others, maybe not, but until you have large studies you can't tease that out," he said.

Koran emphasized that the results of the clinical trial are not definitive, and some people may be helped by therapy involving medication. For others, receiving psychological treatment, perhaps in combination with medication, may prove most effective. But regardless, he said, "People with this disorder should definitely seek treatment."

Source-Eurekalert
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology: